LRMR stock forecast, quote, news & analysis
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform... Show more
Why Larimar Therapeutics (LRMR) Stock Is Down -11.5% in the Last 30 Days
Key Takeaways
- Larimar Therapeutics (LRMR) declined roughly 11.5% over the 30 days through early November, with the stock trading near $2.39 compared with about $2.70 a month earlier.
- The pullback largely reflects a broader risk-off rotation away from pre-revenue, small-cap biotechnology names rather than a single company-specific event.
- Over the trailing quarter, the shares are down more sharply, pressured by analyst price-target reductions and lingering regulatory and safety uncertainty around the lead program.
- Nomlabofusp, the company's lead candidate for Friedreich's ataxia, continues to advance toward completion of a rolling Biologics License Application (BLA) expected in the second half of 2026.
- Safety and manufacturing considerations tied to the accelerated-approval path remain key overhangs for investor sentiment.
- For additional context, explore Price Targets, Earnings, and Forecast data on dedicated pages.
- Investors seeking automated, data-driven market insights can also review Trending AI Robots.
Larimar Therapeutics (LRMR) Company Overview and Market Position
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, focused on developing treatments for complex rare diseases. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein designed to deliver frataxin (FXN) directly to the mitochondria of patients with Friedreich's ataxia, a rare, progressive, and fatal neuromuscular disease caused by a genetic deficiency of frataxin.
The company's proprietary cell-penetrating peptide platform underpins nomlabofusp's mechanism, which aims to address the underlying protein deficiency rather than only manage symptoms. Nomlabofusp has received multiple regulatory designations, including Orphan Drug, Fast Track, Breakthrough Therapy, Rare Pediatric Disease, and European PRIME designations. Investors follow the stock closely because nomlabofusp represents a potential first disease-modifying therapy for Friedreich's ataxia, with the only currently approved treatment not addressing the underlying frataxin deficiency.
Larimar Therapeutics (LRMR) Stock Price Performance: Last 30 Days vs. Quarter
Over the most recent 30-day period, LRMR declined approximately 11.5%, falling from a close near $2.70 to roughly $2.39. The move was not a straight line: the stock experienced a sharp mid-October drawdown before staging a partial recovery that later gave back some of its gains.
The picture is considerably weaker on a quarterly basis. From a close near $4.16 in early August, the shares have fallen roughly 42% to the low-$2 range, and the stock traded near its 52-week low of about $1.92 during October. This longer decline underscores a sustained de-rating across the speculative biotech segment as investors have grown more cautious about funding, regulatory, and safety risks.
What Drove LRMR Stock Price in the Last 30 Days
The recent 30-day decline in LRMR appears driven primarily by market-wide sentiment rather than a single company announcement. In mid-October, a broader risk-off move hit pre-revenue, small-cap biotechnology stocks, with many peers sliding 7% to 10% in the same sessions amid rising long-dated Treasury yields and reduced appetite for speculative, cash-burning names. Larimar moved down sharply alongside that rotation.
Analyst activity also contributed to the cautious tone. Coverage updates have reflected more conservative views on the nomlabofusp regulatory path, including price-target reductions at firms such as Wedbush and Baird and an initiation with a below-consensus target at J.P. Morgan. These revisions underscored ongoing scrutiny of the accelerated-approval pathway, including safety and manufacturing considerations, and weighed on sentiment even as the broader consensus rating has remained constructive.
Finally, uncertainty around the timing and execution of the rolling BLA submission, with remaining modules expected in the second half of 2026, kept some investors on the sidelines during the period.
What Drove LRMR Stock Performance Over the Last Quarter
The sharper quarterly decline reflects a longer-running reassessment of the company's risk profile. Second-quarter results in early August were followed by a series of analyst price-target adjustments through the late summer and early fall, as the market discounted regulatory and manufacturing risks disclosed alongside the nomlabofusp program. Historical safety concerns, including cases of anaphylaxis reported in earlier open-label data, have remained a known overhang on the approval narrative.
At the same time, the broader environment for unprofitable biotech companies has deteriorated. Rising interest rates, tighter financing conditions, and a rotation away from high-duration, pre-revenue assets have pressured valuations across the sector. Larimar's ongoing cash-burn profile and the potential for future dilution have amplified that pressure, even as the company continues to advance nomlabofusp toward a potential submission and confirmatory Phase 3 study.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading bots drawn from a broader universe of hundreds of AI-driven strategies that collectively trade thousands of tickers. Only top-performing and most relevant bots are surfaced in this section, helping traders filter through a large ecosystem of quantitative approaches. The featured robots vary in strategy, timeframe, and performance metrics, so investors can compare different styles before deciding what aligns with their objectives. Browsing the page offers a practical way to observe how algorithmic models are positioned across markets and sectors.
LRMR Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the months ahead. The most important near-term catalyst is the company's next quarterly results, which will provide an update on cash position and clinical progress. Completion of the remaining BLA modules for nomlabofusp and subsequent regulatory feedback from the FDA will be pivotal for the approval timeline, while enrollment and data from the confirmatory Phase 3 study remain important long-term milestones.
Beyond company-specific events, sentiment toward speculative biotechnology, interest-rate movements, and the availability of growth-stage financing will continue to influence the stock. Safety and manufacturing execution for nomlabofusp, along with any additional analyst revisions, also warrant attention. These factors are informational only and do not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LRMR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LRMR turned positive on October 21, 2026. Looking at past instances where LRMR's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LRMR's RSI Indicator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LRMR as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +7.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where LRMR advanced for three days, in 214 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
LRMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 56 cases where LRMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LRMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for LRMR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.949) is normal, around the industry mean (3.498). P/E Ratio (-1.189) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. LRMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LRMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which engages in the research and development of a therapeutic treatment for mitochondrial disorders and Friedreich's ataxia
Industry Biotechnology